3-Deazauridine (Synonyms: NSC 126849) |
カタログ番号GC42260 |
3-デアザウリジンはヌクレオシドアナログです。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 23205-42-7
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
3-デアザウリジンは、ヌクレオシドアナログです。[1]細胞内で3-デアザウリジントリリン酸に変換され、シチジン三リン酸合成酵素を競争的に阻害するため、核酸シチジン5'-トリリン酸(CTP)の生合成を抑制します。 6μMの濃度で使用するとL1210白血病細胞の増殖を抑制し、マウス白血病モデルでは用量依存性に死亡率を減少させます。[2]また、20μMの濃度で使用するとHL-60系列およびMOLT-3系列白血病細胞中のDNAへのデシタビン取り込みが増加します。 L1210白血病マウスモデルでは、3-デアザウリジン(100または150 mg / kg)とデシタビンを併用することで死亡率が減少します。[3]
参考文献:
[1]. Moriconi, W.J., Slavik, M., and Taylor, S. 3-Deazauridine (NSC 126849): An interesting modulator of biochemical response. Invest New Drugs 4(1), 67-84 (1986).
[2]. Bloch, A., Dutschman, G., Currie, B.L., et al. Preparation and biological activity of various 3-deazapyrimidines and related nucleosides. J. Med. Chem. 16(3), 294-297 (1973).
[3]. Raynal, N.J.-M., Momparler, L.F., Rivard, G.E., et al. 3-Deazauridine enhances the antileukemic action of 5-aza-2'-deoxycytidine and targets drug-resistance due to deficiency in deoxycytidine kinase. Leuk. Res.35(1),110-118(2011)。
Cas No. | 23205-42-7 | SDF | |
同義語 | NSC 126849 | ||
Chemical Name | 4-hydroxy-1-β-D-ribofuranosyl-2(1H)-pyridinone | ||
Canonical SMILES | O=C(C=C(O)C=C1)N1[C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2 | ||
Formula | C10H13NO6 | M.Wt | 243.2 |
溶解度 | 10mg/mL in DMSO, 16mg/mL in DMF | Storage | Store at -20°C |
General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. |
Prepare stock solution | |||
1 mg | 5 mg | 10 mg | |
1 mM | 4.1118 mL | 20.5592 mL | 41.1184 mL |
5 mM | 0.8224 mL | 4.1118 mL | 8.2237 mL |
10 mM | 0.4112 mL | 2.0559 mL | 4.1118 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Average Rating: 5
(Based on Reviews and 4 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *